A panel of experts review real-world clinical scenarios to highlight recent advances in the management of multiple myeloma.
EP. 2: Quadruplet Vs Triplet Induction Regimens for Transplant-Eligible NDMMJune 15th 2022
Shared insight on approved quadruplet vs triplet induction regimens for patients with transplant-eligible, newly diagnosed multiple myeloma, evaluated in the GRIFFIN, MASTER and GMMG-HD7 trials.
EP. 5: Patient Profile 2: A 72-Year-Old With Transplant-Ineligible NDMMJune 29th 2022
The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.
EP. 6: Selection and Duration of Therapy in Transplant-Ineligible NDMMJune 29th 2022
Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.
EP. 8: Patient Profile 3: A 57-Year-Old Woman With Triple-Class Refractory MMJuly 6th 2022
Moving to the last patient profile, expert panelists discuss a patient with triple-class refractory multiple myeloma managed with BCMA-targeting bispecific therapy.
EP. 11: Managing AEs Associated With Bispecifics in RRMMJuly 19th 2022
Closing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.